This page is part of the Da Vinci Risk Adjustment FHIR Implementation Guide (v1.0.0: STU 1) based on FHIR R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions
Generated Narrative
Resource "ra-measurereport02"
Risk Adjustment Clinical Data Collection Deadline Extension: 2022-03-31
status: complete
type: individual
measure: Risk Adjustment Model Version 5 - CMS Prescribing Drug Hierarchical Category Condition (CMS-HCC)
subject: Patient/ra-patient01 " EVERYWOMAN"
date: 2021-10-18
reporter: Organization/ra-payer01 "ABC Payer"
period: 2021-01-01 --> 2021-09-30
group
Risk Adjustment Suspect Type Extension: Historic Condition Category Gap (Risk Adjustment Suspect Type Code System#historic)
Evidence Status Extension: Closed Condition Category Gap (Risk Adjustment Evidence Status Code System#closed-gap)
Risk Adjustment Evidence Status Date Extension: 2021-04-01
Hierarchical Status Extension: Hierarchies not applied (Risk Adjustment Hierarchical Status Code System#not-applied)
code: CMS-RxHCC 227: Pulmonary Fibrosis and Other Chronic Lung Disorders (CMS Prescription Drug Hierarchical Condition Categories[5]#227 "Pulmonary Fibrosis and Other Chronic Lung Disorders")
group
Risk Adjustment Suspect Type Extension: Historic Condition Category Gap (Risk Adjustment Suspect Type Code System#historic)
Evidence Status Extension: Open Condition Category Gap (Risk Adjustment Evidence Status Code System#open-gap)
Risk Adjustment Evidence Status Date Extension: 2020-07-01
Hierarchical Status Extension: Hierarchies not applied (Risk Adjustment Hierarchical Status Code System#not-applied)
code: CMS-RxHCC 131: Bipolar Disorders (CMS Prescription Drug Hierarchical Condition Categories[5]#131 "Bipolar Disorders")
group
Risk Adjustment Suspect Type Extension: Suspected Condtion Category Gap (Risk Adjustment Suspect Type Code System#suspected)
Evidence Status Extension: Closed Condition Category Gap (Risk Adjustment Evidence Status Code System#closed-gap)
Risk Adjustment Evidence Status Date Extension: 2021-02-15
Hierarchical Status Extension: Hierarchies not applied (Risk Adjustment Hierarchical Status Code System#not-applied)
code: CMS-RxHCC 30: Diabetes with Chronic Complications (CMS Prescription Drug Hierarchical Condition Categories[5]#30 "Diabetes with Chronic Complications")
group
Risk Adjustment Suspect Type Extension: Suspected Condtion Category Gap (Risk Adjustment Suspect Type Code System#suspected)
Risk Adjustment Evidence Status Date Extension: 2021-04-01
Evidence Status Extension: Closed Condition Category Gap (Risk Adjustment Evidence Status Code System#closed-gap)
Hierarchical Status Extension: Hierarchies not applied (Risk Adjustment Hierarchical Status Code System#not-applied)
code: CMS-RxHCC 43: Morbid Obesity (CMS Prescription Drug Hierarchical Condition Categories[5]#43 "Morbid Obesity")
group
Risk Adjustment Suspect Type Extension: Suspected Condtion Category Gap (Risk Adjustment Suspect Type Code System#suspected)
Evidence Status Extension: Pending Condition Category Gap (Risk Adjustment Evidence Status Code System#pending)
Risk Adjustment Evidence Status Date Extension: 2021-09-29
Hierarchical Status Extension: Hierarchies not applied (Risk Adjustment Hierarchical Status Code System#not-applied)
code: CMS-RxHCC 31: Diabetes without Complications (CMS Prescription Drug Hierarchical Condition Categories[5]#31 "Diabetes without Complications")
group
Risk Adjustment Suspect Type Extension: Net-New Condition Category (Risk Adjustment Suspect Type Code System#net-new)
Evidence Status Extension: Pending Condition Category Gap (Risk Adjustment Evidence Status Code System#pending)
Risk Adjustment Evidence Status Date Extension: 2021-09-29
Hierarchical Status Extension: Hierarchies not applied (Risk Adjustment Hierarchical Status Code System#not-applied)
code: CMS-RxHCC 226: Chronic Obstructive Pulmonary Disease and Asthma (CMS Prescription Drug Hierarchical Condition Categories[5]#226 "Chronic Obstructive Pulmonary Disease and Asthma")
evaluatedResource: